Full Press Release Details
IMMUTEP GRANTED CHINESE PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A
SYDNEY, AUSTRALIA 2 November 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP)
( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new
patent (number ZL 201610221687) entitled Use of recombinant LAG-3 or the derivatives thereof for eliciting a monocyte immune response by the Chinese Patent Office. The patent forms part of a broad
and growing portfolio of patent families for the Company s lead product candidiate eftilagimod alpha ( efti or IMP321 ) in key global markets including China.
This new Chinese patent follows the grant of the corresponding European, Japanese and United States patents announced previously. The claims of the new patent
relate to methods of use of (a) Immutep s efti which is a LAG-3 fusion protein (LAG-3Ig) and (b) a chemotherapy agent in combination for the manufacture
of a preparation for the treatment of cancer. The patent provides protection in mainland China and the expiry date is 3 October 2028.
is owned by Immutep S.A.S. and exclusively licensed to Immutep s partner in China, EOC Pharma ( EOC ).
Immutep CEO, Marc Voigt,
noted: We are making good progress building our global patent estate around our LAG-3 development pipeline, including lead candidate efti which has delivered promising clinical data in various
settings. We will continue to make these important investments and are especially pleased to be working so closely with our Chinese partner, EOC Pharma, as they expand their clinical development of efti for the Chinese market.
EOC Pharma CEO, Xiaoming Zou, said: We are investing in the development of efti for the local market in China and are very pleased with the steps
being taken by our partner, Immutep, to build a broad portfolio of patent families around this unique candidate. These are important and ongoing steps in the complex process of bringing innovative medicines to the market for patients.
Efti is exclusively licensed by
Immutep to EOC Pharma for the territory of Greater China (namely mainland China, Hong Kong S.A.R, Macao S.A.R. and Taiwan). Under its agreement with Immutep, EOC will make further milestone payments to the Company if efti achieves specific
development milestones, as well as pay sales-based royalties. Immutep retains the rights to efti outside the territory of Greater China.
EOC Pharma is an integrated biopharmaceutical company focusing on the discovery, research, development and commercialisation of innovative
oncology products. With an insight-driven strategy and integrated business platform, EOC Pharma strives to build a portfolio of products with strategic synergies from independent R&D and licensing and enrich the product pipeline with first- and
best -in-class oncology drugs to benefit the millions of patients who currently have limited access to high quality oncology treatments in China.
Level 12, 95 Pitt Street, Sydney NSW 2000
Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.
Immutep s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep
is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being
developed by Immutep s large pharmaceutical partners.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the
Further information can be found on the Company s website www.immutep.com or by contacting:
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com
announcement was authorised for release by the Board of Immutep Limited.
Level 12, 95 Pitt Street, Sydney NSW 2000